(Q45361593)

English

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

scientific article published on 12 November 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Manfred Welslau

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Veronique Diéras

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Sara A Hurvitz

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Deepa Lalla

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Liang Fang

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Betsy Althaus

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Ellie Guardino

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

David Miles

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

0 references

publication date

12 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

120

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

642-651

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24222194%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Patient-reported outcomes in cancer: a review of recent research and policy initiatives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

21 January 2018

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

7 January 2021

based on heuristic

inferred from DOI database lookup

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28465

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45361593&oldid=2075841520"